Alliancebernstein L.P. Alx Oncology Holdings Inc Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Alliancebernstein L.P. holds 71,730 shares of ALXO stock, worth $131,265. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,730

Previous 71,730 -0.0%

Holding current value

$131,265

Previous $432,000 69.91%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.84 - $17.56 $192,369 - $578,426	32,940 Added 84.92%	71,730 $432,000
Q1 2024 May 14, 2024	SELL	$10.95 - $16.79 $16,425 - $25,185	-1,500 Reduced 3.72%	38,790 $432,000
Q3 2023 Nov 14, 2023	BUY	$4.19 - $7.35 $7,164 - $12,568	1,710 Added 4.43%	40,290 $193,000
Q2 2023 Aug 15, 2023	BUY	$4.37 - $9.56 $37,494 - $82,024	8,580 Added 28.6%	38,580 $289,000
Q1 2023 May 15, 2023	BUY	$4.52 - $11.71 $6,779 - $17,565	1,500 Added 5.26%	30,000 $135,000
Q4 2022 Feb 14, 2023	BUY	$9.51 - $12.95 $29,481 - $40,145	3,100 Added 12.2%	28,500 $321,000
Q3 2022 Nov 15, 2022	SELL	$8.23 - $15.14 $19,752 - $36,336	-2,400 Reduced 8.63%	25,400 $243,000
Q2 2022 Aug 15, 2022	BUY	$5.89 - $19.46 $42,997 - $142,058	7,300 Added 35.61%	27,800 $225,000
Q4 2021 Feb 14, 2022	SELL	$21.49 - $74.4 $64,469 - $223,200	-3,000 Reduced 12.77%	20,500 $441,000
Q2 2021 Jul 30, 2021	BUY	$52.2 - $75.23 $57,420 - $82,753	1,100 Added 4.91%	23,500 $1.29 Million
Q1 2021 May 06, 2021	BUY	$62.84 - $87.68 $477,584 - $666,368	7,600 Added 51.35%	22,400 $1.65 Million
Q4 2020 Feb 08, 2021	BUY	$34.11 - $112.26 $504,828 - $1.66 Million	14,800 New	14,800 $1.28 Million

Others Institutions Holding ALXO

# of Institutions

101

Shares Held

39.7M

Call Options Held

134K

Put Options Held

17.4K

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $74.6M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Alx Oncology Holdings Inc Transaction History